NO330269B1 - Peptid, DNA, vektor, celle, fremgangsmate for undersokelse av hvorvidt et peptid som kodes for av et cDNA som skal testes inneholder sekretorisk evne, samt fremgangsmate for isolering av et cDNA som koder for et peptid med sekretorisk evne - Google Patents
Peptid, DNA, vektor, celle, fremgangsmate for undersokelse av hvorvidt et peptid som kodes for av et cDNA som skal testes inneholder sekretorisk evne, samt fremgangsmate for isolering av et cDNA som koder for et peptid med sekretorisk evne Download PDFInfo
- Publication number
- NO330269B1 NO330269B1 NO20002670A NO20002670A NO330269B1 NO 330269 B1 NO330269 B1 NO 330269B1 NO 20002670 A NO20002670 A NO 20002670A NO 20002670 A NO20002670 A NO 20002670A NO 330269 B1 NO330269 B1 NO 330269B1
- Authority
- NO
- Norway
- Prior art keywords
- cdna
- peptide
- cell
- vector
- secretory
- Prior art date
Links
- 239000002299 complementary DNA Substances 0.000 title claims description 86
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 55
- 230000003248 secreting effect Effects 0.000 title claims description 50
- 238000000034 method Methods 0.000 title claims description 43
- 239000013598 vector Substances 0.000 title claims description 41
- 210000004027 cell Anatomy 0.000 claims description 72
- 230000004663 cell proliferation Effects 0.000 claims description 18
- 230000002062 proliferating effect Effects 0.000 claims description 12
- 108010002386 Interleukin-3 Proteins 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 238000011144 upstream manufacturing Methods 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 19
- 101150001753 MPL gene Proteins 0.000 description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 102000040739 Secretory proteins Human genes 0.000 description 15
- 108091058545 Secretory proteins Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 14
- 102000037865 fusion proteins Human genes 0.000 description 13
- 108020001507 fusion proteins Proteins 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 239000012634 fragment Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 102000000646 Interleukin-3 Human genes 0.000 description 7
- 229940076264 interleukin-3 Drugs 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 102000012410 DNA Ligases Human genes 0.000 description 5
- 108010061982 DNA Ligases Proteins 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000006471 dimerization reaction Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 210000000352 storage cell Anatomy 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 101001033276 Mus musculus Interleukin-3 Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100034196 Thrombopoietin receptor Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 102000046157 human CSF2 Human genes 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 102100036509 Erythropoietin receptor Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000445359 Mus haussa Species 0.000 description 1
- 101100261153 Mus musculus Mpl gene Proteins 0.000 description 1
- 241000714199 Myeloproliferative leukemia virus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 108010070774 Thrombopoietin Receptors Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32491297 | 1997-11-26 | ||
| PCT/JP1998/005326 WO1999026978A1 (fr) | 1997-11-26 | 1998-11-26 | Procede de piegeage de signal-sequence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20002670D0 NO20002670D0 (no) | 2000-05-25 |
| NO20002670L NO20002670L (no) | 2000-07-25 |
| NO330269B1 true NO330269B1 (no) | 2011-03-14 |
Family
ID=18171016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002670A NO330269B1 (no) | 1997-11-26 | 2000-05-25 | Peptid, DNA, vektor, celle, fremgangsmate for undersokelse av hvorvidt et peptid som kodes for av et cDNA som skal testes inneholder sekretorisk evne, samt fremgangsmate for isolering av et cDNA som koder for et peptid med sekretorisk evne |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6866998B1 (ja) |
| EP (1) | EP1033374B1 (ja) |
| JP (1) | JP3499528B2 (ja) |
| KR (1) | KR100452008B1 (ja) |
| CN (1) | CN1214041C (ja) |
| AU (1) | AU1260799A (ja) |
| CA (1) | CA2311678C (ja) |
| HK (1) | HK1032065A1 (ja) |
| IL (2) | IL136310A0 (ja) |
| NO (1) | NO330269B1 (ja) |
| RU (1) | RU2230751C2 (ja) |
| WO (1) | WO1999026978A1 (ja) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7879318B2 (en) * | 2006-01-23 | 2011-02-01 | Mcw Research Foundation, Inc. | Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand |
| WO2011148983A1 (ja) | 2010-05-25 | 2011-12-01 | 独立行政法人国立がん研究センター | 生体外で自己複製可能な誘導前がん幹細胞又は誘導悪性幹細胞、これらの製造方法、及び、これらの細胞の応用 |
| TW201335372A (zh) | 2011-11-30 | 2013-09-01 | Nat Cancer Ct | 誘導惡性幹細胞 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2879303B2 (ja) | 1993-01-14 | 1999-04-05 | 佑 本庶 | ｃＤＮＡライブラリーの作製方法、および新規なポリペプチドとそれをコードするＤＮＡ |
| US5536637A (en) * | 1993-04-07 | 1996-07-16 | Genetics Institute, Inc. | Method of screening for cDNA encoding novel secreted mammalian proteins in yeast |
| US5675062A (en) * | 1994-07-18 | 1997-10-07 | President And Fellows Of Harvard College | Cellular basis of transplant arteriosclerosis in mice |
| WO1996040904A1 (en) | 1995-06-07 | 1996-12-19 | Zymogenetics, Inc. | Secretion leader trap cloning method |
| JP2002238557A (ja) | 1996-07-23 | 2002-08-27 | Fujisawa Pharmaceut Co Ltd | トランスメンブレントラップ法 |
| JPH1132779A (ja) | 1997-07-24 | 1999-02-09 | Fujita Gakuen | 蛋白質の遺伝子クローニング法 |
-
1998
- 1998-11-26 AU AU12607/99A patent/AU1260799A/en not_active Abandoned
- 1998-11-26 EP EP98955942A patent/EP1033374B1/en not_active Expired - Lifetime
- 1998-11-26 KR KR10-2000-7005715A patent/KR100452008B1/ko not_active IP Right Cessation
- 1998-11-26 CA CA002311678A patent/CA2311678C/en not_active Expired - Fee Related
- 1998-11-26 RU RU2000116268/13A patent/RU2230751C2/ru not_active IP Right Cessation
- 1998-11-26 JP JP2000522134A patent/JP3499528B2/ja not_active Expired - Fee Related
- 1998-11-26 IL IL13631098A patent/IL136310A0/xx active IP Right Grant
- 1998-11-26 US US09/555,165 patent/US6866998B1/en not_active Expired - Fee Related
- 1998-11-26 WO PCT/JP1998/005326 patent/WO1999026978A1/ja not_active Application Discontinuation
- 1998-11-26 CN CNB988129698A patent/CN1214041C/zh not_active Expired - Fee Related
-
2000
- 2000-05-23 IL IL136310A patent/IL136310A/en not_active IP Right Cessation
- 2000-05-25 NO NO20002670A patent/NO330269B1/no not_active IP Right Cessation
-
2001
- 2001-03-05 HK HK01101587.6A patent/HK1032065A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20002670D0 (no) | 2000-05-25 |
| EP1033374B1 (en) | 2012-08-01 |
| CA2311678C (en) | 2006-09-19 |
| JP3499528B2 (ja) | 2004-02-23 |
| CN1285847A (zh) | 2001-02-28 |
| IL136310A0 (en) | 2001-05-20 |
| EP1033374A4 (en) | 2006-06-14 |
| RU2230751C2 (ru) | 2004-06-20 |
| WO1999026978A1 (fr) | 1999-06-03 |
| CA2311678A1 (en) | 1999-06-03 |
| AU1260799A (en) | 1999-06-15 |
| HK1032065A1 (en) | 2001-07-06 |
| CN1214041C (zh) | 2005-08-10 |
| KR100452008B1 (ko) | 2004-10-08 |
| EP1033374A1 (en) | 2000-09-06 |
| NO20002670L (no) | 2000-07-25 |
| IL136310A (en) | 2007-06-03 |
| US6866998B1 (en) | 2005-03-15 |
| KR20010032473A (ko) | 2001-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1243650B1 (en) | Process for constructing a cDNA library | |
| US7968681B2 (en) | c-MET kinase binding proteins | |
| KR20210019993A (ko) | Τ 세포 수용체 및 이를 발현하는 조작된 세포 | |
| JP2004000282A (ja) | 酵母におけるｇタンパク質結合受容体の発現 | |
| CN112375784A (zh) | 制备重组新型冠状病毒Spike蛋白的方法 | |
| AU2002222454B2 (en) | Improvement of homogeneity and secretion of recombinant proteins in mammalian systems | |
| CN111440244A (zh) | 靶向vegfr2的转移性癌疫苗 | |
| US20100184619A1 (en) | Method for analyzing organelle-localized protein and material for analysis | |
| JPH07250689A (ja) | タンパク質−タンパク質相互作用を検出するためのペリプラズム膜結合系 | |
| CA2407872C (en) | Receptor-based interaction trap | |
| NO330269B1 (no) | Peptid, DNA, vektor, celle, fremgangsmate for undersokelse av hvorvidt et peptid som kodes for av et cDNA som skal testes inneholder sekretorisk evne, samt fremgangsmate for isolering av et cDNA som koder for et peptid med sekretorisk evne | |
| JP3678233B2 (ja) | 核移行蛋白質をコードする遺伝子の検索法 | |
| CN112877309B (zh) | 一种N端延长型PTEN亚型PTENζ蛋白及其编码基因和应用 | |
| WO1999053033A1 (en) | Methods and compositions for high yield production of eukaryotic proteins | |
| AU2002301561B2 (en) | Signal Sequence Trapping Method | |
| CN112867791A (zh) | 用于转导蛋白质-蛋白质相互作用的新方法 | |
| CN114703229B (zh) | 一种基于人源细胞的表面展示技术及靶向hbv受体的多肽及其应用 | |
| EP0939119A1 (en) | Transmembrane trapping methods | |
| CN115850441B (zh) | 一种特异性靶向降解egfr及其突变体的重组蛋白、制备方法及其应用 | |
| CN108191979B (zh) | 一种荧光互补检测人趋化因子生物学活性的方法 | |
| JP2003505043A (ja) | 血清アルブミンのキメラポリペプチド及びそれらに関する利用 | |
| JP2000152792A (ja) | 新規ｇ蛋白質共役型受容体蛋白質、ｄｎａおよびその用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: TOSHIO KITAMURA, JP |
|
| MM1K | Lapsed by not paying the annual fees |